

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

For the Month of March 2022

Commission File Number 001-35948

**Kamada Ltd.**  
(Translation of registrant's name into English)

**2 Holzman Street**  
**Science Park, P.O. Box 4081**  
**Rehovot 7670402**  
**Israel**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_

This Form 6-K is being incorporated by reference into the Registrant's Form S-8 Registration Statements, File Nos. [333-192720](#), [333-207933](#), [333-215983](#), [333-222891](#) and [333-233267](#).

---

---

The following exhibit is attached:

99.1 [Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2021 Financial Results, and Host Conference Call on March 15, 2022](#)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 2, 2022

**KAMADA LTD.**

By: /s/ Yifat Philip  
Yifat Philip  
Vice President General Counsel and  
Corporate Secretary

EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION

---

99.1	<a href="#"><u>Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2021 Financial Results, and Host Conference Call on March 15, 2022</u></a>
------	--

**Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2021 Financial Results, and Host Conference Call on March 15, 2022**

**Rehovot, Israel, March 2, 2022** -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2021, prior to the open of the U.S. financial markets on Tuesday, March 15, 2022.

Kamada management will host an investment community conference call on Tuesday, March 15, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-407-0792 (from within the U.S.), 1 809-406-247 (from Israel), or 201-689-8263 (International) and entering the conference identification number: 13727620. The call will also be webcast live on the Internet at:

[https://viaid.webcasts.com/starthere.jsp?ei=1533883&tp\\_key=876a5d54ec](https://viaid.webcasts.com/starthere.jsp?ei=1533883&tp_key=876a5d54ec)

The call will also be archived for 90 days on the Company's website at [www.kamada.com](http://www.kamada.com).

**About Kamada**

Kamada Ltd. (the "Company") is a global leader in the plasma-derived hyperimmune market and a specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company's strategy is to evolve into a fully integrated specialty plasma company, with a core focus on driving profitable growth from our current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical market. The Company's commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRRAB® as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. The Company has additional four plasma-derived products which are registered in markets outside the U.S. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has a diverse portfolio of development pipeline products including an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added nine biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2025. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company's lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

###

**CONTACTS:**

Chaime Orlev  
Chief Financial Officer  
[IR@kamada.com](mailto:IR@kamada.com)

Bob Yedid  
LifeSci Advisors, LLC  
646-597-6989  
[Bob@LifeSciAdvisors.com](mailto:Bob@LifeSciAdvisors.com)